Head and neck squamous cell carcinoma (HNSCC) contribute to a significant global cancer burden. Developments in current therapeutic approaches have improved patient outcomes but have limited efficacy in patients with unresectable and/or recurrent HNSCC. RM-1929 near-infrared photoimmunotherapy (NIR-PIT) is an emerging treatment that is currently being investigated in a Phase III clinical trial and has been conditionally approved for the treatment of unresectable and/or recurrent HNSCC in Japan. Here, we collect a series of case reports and clinical trial data to assess the efficacy of RM-1929 NIR-PIT. Disease control rates ranged from 66.7 to 100% across these studies, and overall response rates ranged from 43.3 to 100%, suggesting positive clinical outcomes. Low-grade postoperative localized pain and edema were the most frequently reported side effects, and preliminary reports on quality of life and pain levels suggest that RM-1929 NIR-PIT does not significantly decrease quality of life and is manageable with existing pain management strategies, including opioids. These preliminary data in real-world use of RM-1929 NIR-PIT show that it is a well-tolerated therapy that has clinically meaningful outcomes for patients with unresectable and/or recurrent HNSCC.
头颈部鳞状细胞癌（HNSCC）在全球范围内造成了显著的癌症负担。当前治疗手段的发展虽改善了患者预后，但对于不可切除和/或复发性HNSCC患者的疗效仍有限。RM-1929近红外光免疫疗法（NIR-PIT）是一种新兴的治疗方法，目前正处于III期临床试验阶段，并已在日本有条件获批用于治疗不可切除和/或复发性HNSCC。本文通过汇总系列病例报告及临床试验数据，评估RM-1929 NIR-PIT的疗效。各项研究显示疾病控制率介于66.7%至100%之间，总体缓解率达43.3%至100%，提示其具有积极的临床效果。低级别的术后局部疼痛和水肿是最常见的不良反应，而关于生活质量和疼痛水平的初步报告表明，RM-1929 NIR-PIT不会显著降低生活质量，且通过现有疼痛管理策略（包括阿片类药物）可有效控制症状。这些RM-1929 NIR-PIT在真实世界应用的初步数据表明，该疗法耐受性良好，能为不可切除和/或复发性HNSCC患者带来具有临床意义的治疗效果。
肿瘤(癌症)患者之家